2 results
Approved WMOCompleted
To confirm superiority of liraglutide compared to placebo, both adjunct to insulin treatment, on glycaemic control, after 26 weeks of treatment in subjects with established type 1 diabetes in inadequate glycaemic control.
Approved WMOWill not start
1. To assess the efficacy of liraglutide in patients with schizophrenia and diabetes ona. Glycaemic controlb. Body weightc. Cardiovascular risk factors (blood pressure, lipids)2. To assess the safety of liraglutide in these patients3. To assess the…